تداخلات نورتريبتيلين

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (نشرة إبراتروبيوم، التداخلات الدوائية)

Antidepressants: tricyclic antidepressants ↑ tricyclic antidepressants Coadministration with REYATAZ has the potential to produce serious and/or life-threatening adverse events and has not been studied. (نشرة أتازانافير، التداخلات الدوائية)

Starting Pamelor in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome ( see WARNINGS and DOSAGE AND ADMINISTRATION ). (نشرة نورتريبتيلين، موانع الاستعمال)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (نشرة أزيلاستين وفلوتيكازون، التحذيرات والاحتياطات)

The use of LUNESTA with other sedative-hypnotics at bedtime or the middle of the night is not recommended. (نشرة إسزوبيكلون، التحذيرات والاحتياطات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (نشرة أكليدينيوم، التداخلات الدوائية)

• Effects on Driving and Operating Machinery: Patients receiving • alprazolam XR should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (نشرة ألبرازولام، التحذيرات والاحتياطات)

…AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOD WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH ALCOHOL, BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Belladonna and opium suppositories expose patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة البلادونا والأفيون، تحذير مؤطر)

…Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly dependent on CYP3A for clearance and for which… (نشرة إلفيتيغرافير وكوبيسيستات وإمتريسيتابين وتينوفوفير، موانع الاستعمال)

الجمع بين الكحول والأدوية المهدئة (الأفيونيات، البنزوديازيبينات، أدوية النوم، مرخيات العضلات) قد يسبب نعاسًا خطيرًا وتباطؤًا في التنفس وجرعة زائدة. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

Selective Serotonin Reuptake Inhibitors/Serotonin and Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors [see Warnings and Precautions (5.7) ]. (نشرة إليتريبتان، التداخلات الدوائية)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة أمفيتامين، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (نشرة أمفيتامين وديكستروأمفيتامين، التحذيرات والاحتياطات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (نشرة أوكسيبات الصوديوم، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوكسيكودون، تحذير مؤطر)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Oxycodone hydrochloride tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة أوكسيكودون وباراسيتامول، تحذير مؤطر)

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوكسيمورفون، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (نشرة أولوباتادين، التحذيرات والاحتياطات)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (نشرة أولوباتادين وموميتازون، التحذيرات والاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة أوليسيريدين، تحذير مؤطر)

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (نشرة أوميكليدينيوم، التداخلات الدوائية)

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (نشرة أوميكليدينيوم وفيلانتيرول، التداخلات الدوائية)

S e ro t o ni n Syndrome: Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. (نشرة أوندانسيترون، التحذيرات والاحتياطات)

CONTRAINDICATIONS Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with Pamelor or within 14 days of stopping treatment with Pamelor is contraindicated because of an increased risk of serotonin syndrome. (نشرة نورتريبتيلين، موانع الاستعمال)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة باراسيتامول وكودايين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs. (نشرة بالونوسيترون، التحذيرات والاحتياطات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

…PROMETHAZINE AND RESPIRATORY DEPRESSION IN CHILDREN; MEDICATION ERRORS; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Promethazine HCl and Codeine Phosphate Oral Solution exposes patients and other users to the risks… (نشرة بروميثازين وكودايين، تحذير مؤطر)

…MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS Addiction, Abuse, and Misuse Pentazocine and Naloxone Tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to… (نشرة بنتازوسين ونالوكسون، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوبرينورفين، تحذير مؤطر)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (نشرة بوبرينورفين ونالوكسون، التداخلات الدوائية)

Concomitant use of opioids or a barbiturate with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وأسبرين وكافيين وكودايين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتالبيتال وباراسيتامول وكافيين وكودايين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بوتورفانول، تحذير مؤطر)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (نشرة بوسبيرون، التحذيرات)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة بيثيدين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة تابنتادول، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ترامادول، تحذير مؤطر)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ترامادول وباراسيتامول، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

• Effects on Driving and Operating Heavy Machinery : Patients receiving triazolam should be cautioned against driving or operating heavy machinery, as well as avoiding concomitant use with alcohol and other CNS depressant drugs. (نشرة تريازولام، التحذيرات والاحتياطات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (نشرة تيوتروبيوم، التداخلات الدوائية)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (نشرة دارونافير، موانع الاستعمال)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated in patients receiving certain co-administered drugs for which altered plasma… (نشرة دارونافير وكوبيسيستات، موانع الاستعمال)

…Pharmacology (12.3) ] • Concomitant use of drugs or herbal products that prolong the QT interval and might increase the risk of torsade de pointes, such as phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, and Class I and III antiarrhythmics • Liver or lung toxicity related to the previous use of amiodarone • QTc interval… (نشرة درونيدارون، موانع الاستعمال)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (نشرة ديفينوكسيلات وأتروبين، موانع الاستعمال)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (نشرة ديفينوكسين وأتروبين، التحذيرات)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (نشرة ديكستروأمفيتامين، التداخلات الدوائية)

Serotonin syndrome: Use of NUEDEXTA with selective serotonin reuptake inhibitor (SSRIs) or tricyclic antidepressants increases the risk. (نشرة ديكستروميثورفان وكينيدين، التحذيرات والاحتياطات)

CONTRAINDICATIONS Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with Pamelor or within 14 days of stopping treatment with Pamelor is contraindicated because of an increased risk of serotonin syndrome. (نشرة نورتريبتيلين، موانع الاستعمال)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (نشرة ريتونافير، تحذير مؤطر)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (نشرة ريفاستيغمين، التداخلات الدوائية)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ريميفنتانيل، تحذير مؤطر)

The use of zaleplon with other sedative-hypnotics at bedtime or the middle of the night is not recommended (see ). (نشرة زاليبلون، التحذيرات)

The use of Zolpidem Tartrate with other sedative-hypnotics (including other zolpidem products) at bedtime or the middle of the night is not recommended. (نشرة زولبيديم، التحذيرات والاحتياطات)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة زيبراسيدون، التحذيرات والاحتياطات)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (نشرة سترات البوتاسيوم، موانع الاستعمال)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (نشرة سوماتريبتان، التداخلات الدوائية)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Clinical Impact: Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.11)] . (نشرة سوماتريبتان ونابروكسين، التداخلات الدوائية)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (نشرة سيبروفلوكساسين، التداخلات الدوائية)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (نشرة سيتريزين، التحذيرات والاحتياطات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs. (نشرة سيكلوبنزابرين، موانع الاستعمال)

CONTRAINDICATIONS Monoamine Oxidase Inhibitors (MAOIs) The use of MAOIs intended to treat psychiatric disorders with Pamelor or within 14 days of stopping treatment with Pamelor is contraindicated because of an increased risk of serotonin syndrome. (نشرة نورتريبتيلين، موانع الاستعمال)

Serotonin syndrome has been reported with granisetron products, alone but particularly with concomitant use of serotonergic drugs. (نشرة غرانيسيترون، التحذيرات والاحتياطات)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (نشرة غلوكاغون، التداخلات الدوائية)

• Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (نشرة غليكوبيرولات، التحذيرات والاحتياطات)

Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [ see Warnings and Precautions (5.7) ]. (نشرة فروفاتريبتان، التداخلات الدوائية)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

THESE ARE MOST FREQUENT IN PATIENTS WHO HAVE BEEN ON BENZODIAZEPINES FOR LONG-TERM SEDATION OR IN OVERDOSE CASES WHERE PATIENTS ARE SHOWING SIGNS OF SERIOUS CYCLIC ANTIDEPRESSANT OVERDOSE. (نشرة فلومازينيل، تحذير مؤطر)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Pamelor, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (نشرة نورتريبتيلين، التحذيرات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (نشرة فوسامبرينافير، موانع الاستعمال)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (نشرة كاربامازيبين، موانع الاستعمال)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (نشرة كاربينوكسامين، التحذيرات والاحتياطات)

When possible, avoid concomitant use, with other anticholinergic medications because the risk for anticholinergic toxicity or severe gastrointestinal adverse reactions is increased [see Warnings and Precautions ( 5.7 ), Drug Interactions ( 7.1 )]. (نشرة كلوزابين، التحذيرات والاحتياطات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (نشرة كلونيدين، التحذيرات والاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة كودايين، تحذير مؤطر)

Benzodiazepines, Opioid Analgesics, or other CNS Depressants : Concomitant use may result in profound sedation, respiratory depression, coma, or death. (نشرة كيتامين، التداخلات الدوائية)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (نشرة كيتوكونازول، موانع الاستعمال)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (نشرة كينيدين، موانع الاستعمال)

…Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma concentrations… (نشرة لوبينافير وريتونافير، موانع الاستعمال)

Caution patients receiving LOREEV XR against operating machinery or driving a motor vehicle as well to avoid the concomitant use of alcohol and other CNS depressant drugs during treatment ( 5.4 , 7 ) (نشرة لورازيبام، التحذيرات والاحتياطات)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (نشرة ليثيوم، التحذيرات والاحتياطات)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ليسديكسامفيتامين، التحذيرات والاحتياطات)

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة ليفورفانول، تحذير مؤطر)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (نشرة ليفوسيتريزين، التحذيرات والاحتياطات)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Starting Pamelor in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome ( see WARNINGS and DOSAGE AND ADMINISTRATION ). (نشرة نورتريبتيلين، موانع الاستعمال)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة مورفين، تحذير مؤطر)

If concomitant use with another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (نشرة ميتاكسالون، التحذيرات والاحتياطات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (نشرة ميتوكلوبراميد، التحذيرات والاحتياطات)

Managing Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants Concomitant use with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, is a risk factor for respiratory depression and death [see Warnings and Precautions ( 5.2 )]. (نشرة ميثادون، تحذير مؤطر)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (نشرة ميثامفيتامين، التحذيرات والاحتياطات)

WARNING: PERSONNEL AND EQUIPMENT FOR MONITORING AND RESUSCITATION AND RISKS FROM CONCOMITANT USE WITH OPIOID ANALGESICS AND OTHER SEDATIVE-HYPNOTICS Personnel and Equipment for Monitoring and Resuscitation Only personnel trained in the administration of procedural sedation, and not involved in the conduct of the diagnostic or therapeutic procedure, should administer… (نشرة ميدازولام، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (نشرة ميلناسيبران، التحذيرات والاحتياطات)

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)] . (نشرة ناراتريبتان، التداخلات الدوائية)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة نالبوفين، تحذير مؤطر)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (نشرة نالميفين، التحذيرات والاحتياطات)

الجمع بين نبتة سانت جون ومضادات الاكتئاب والأدوية السيروتونينية الأخرى يزيد خطر متلازمة السيروتونين. (NCCIH, St. John's Wort)

…(selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin receptor 2A antagonist: flibanserin • Vasopressin receptor antagonists: tolvaptan ➢ Drugs that… (نشرة نيرماتريلفير وريتونافير، موانع الاستعمال)

Anyone considering the use of nortriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. (نشرة نورتريبتيلين، تحذير مؤطر)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (نشرة هيدروكسيزين، الاحتياطات)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة هيدروكودون، تحذير مؤطر)

…LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P4503A4 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE AND IBUPROFEN TABLETS Addiction,… (نشرة هيدروكودون وإيبوبروفين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. (نشرة هيدروكودون وباراسيتامول، تحذير مؤطر)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION;… (نشرة هيدروكودون وكلورفينيرامين، تحذير مؤطر)

…ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; MEDICATION ERRORS; CYTOCHROME P450 3A4 INTERACTION; CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; INTERACTION WITH ALCOHOL; NEONATAL OPIOID WITHDRAWAL SYNDROME Addiction, Abuse, and Misuse Hydrocodone bitartrate and homatropine methylbromide exposes patients and… (نشرة هيدروكودون وهوماتروبين، تحذير مؤطر)

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death . (نشرة هيدرومورفون، تحذير مؤطر)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة أريبيبرازول، التحذيرات والاحتياطات)

Although behaviors such as sleep-driving may occur with sedative-hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with sedative-hypnotics appears to increase the risk of such behaviors, as does the use of sedative-hypnotics at doses exceeding the maximum recommended dose. (نشرة إستازولام، التحذيرات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use SAPHRIS with caution in patient who may experience these conditions. (نشرة أسينابين، التحذيرات والاحتياطات)

Monoamine Oxidase Inhibitors (MAOIs) ( See CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION . ) Serotonergic Drugs ( See CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION . ) (نشرة نورتريبتيلين، التداخلات الدوائية)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (نشرة ألوبيورينول، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة أمينوفيلين، التداخلات الدوائية)

Table 5: Amiodarone Drug Interactions Concomitant Drug Class/Name Examples Clinical Comment QT Prolonging Drugs class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents Increased risk of Torsade de Pointes. (نشرة أميودارون، التداخلات الدوائية)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (نشرة إنكوبوتولينوم توكسين A، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Patients should be warned that the effects of alcohol or other CNS-depressant drugs may be additive to those of Oxazepam, possibly requiring adjustment of dosage or elimination of such agents. (نشرة أوكسازيبام، التحذيرات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (نشرة أونابوتولينوم توكسين A، التداخلات الدوائية)

SSRIs, Tricyclics and Related Antidepressants Venlafaxine Monitor for adverse reactions. (نشرة إيتراكونازول، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Antidepressant: Bupropion Sertraline ↓ bupropion * ↓ sertraline * Increases in bupropion dosage should be guided by clinical response. (نشرة إيفافيرينز، التداخلات الدوائية)

Antidepressants: Bupropion ↓ bupropion Increases in bupropion dosage should be guided by clinical response. (نشرة إيفافيرينز ولاميفودين وتينوفوفير، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use FANAPT with caution in patients who may experience these conditions. (نشرة إيلوبيريدون، التحذيرات والاحتياطات)

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (نشرة إيلوكسادولين، التداخلات الدوائية)

Patients should also be cautioned that the central nervous system depressant effects of intrathecal baclofen may be additive to those of alcohol and other CNS depressants. (نشرة باكلوفين، التحذيرات والاحتياطات)

The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli. (نشرة بروبوفول، التحذيرات والاحتياطات)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (نشرة بروكاييناميد، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

When the decision is made to co-prescribe LYRICA CR with another CNS depressant, particularly an opioid, or to prescribe LYRICA CR to patients with underlying respiratory impairment, monitor patients for symptoms of respiratory depression and sedation, and consider initiating LYRICA CR at a low dose. (نشرة بريغابالين، التحذيرات والاحتياطات)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (نشرة بريكسبيبرازول، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Use with CNS depressants may result in an additive or potentiating effect. (نشرة بريمونيدين، التداخلات الدوائية)

Use with CNS depressants may result in an additive or potentiating effect. (نشرة بريمونيدين وتيمولول، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (نشرة بوبيفاكايين، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Butalbital and acetaminophen may enhance the effects of:other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. (نشرة بوتالبيتال وباراسيتامول، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Concomitant Use with Midazolam : Noxafil can prolong hypnotic/sedative effects. (نشرة بوساكونازول، التحذيرات والاحتياطات)

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when FYCOMPA is used with other drugs with sedative properties because of potential additive effects. (نشرة بيرامبانيل، التحذيرات والاحتياطات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (نشرة بيرفينازين، التحذيرات)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (نشرة بيريدوستيغمين، التحذيرات والاحتياطات)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use caution when midazolam or triazolam is concomitantly administered with BIXLENVO. (نشرة بيكتيغرافير وإمتريسيتابين وتينوفوفير ألافيناميد، التداخلات الدوائية)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (نشرة بيلوكاربين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (نشرة بيموزيد، التحذيرات)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (نشرة بينازيبريل وهيدروكلوروثيازيد، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (نشرة تريفلوبيرازين، التحذيرات)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (نشرة تريميثوبنزاميد، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Caution should be used when topiramate extended-release capsules are prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. (نشرة توبيرامات، التحذيرات والاحتياطات)

…quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin, levofloxacin, ofloxacin); and certain anti-emetics (e.g., ondansetron, granisetron). (نشرة توريميفين، التداخلات الدوائية)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (نشرة توكسين البوتولينوم من النمط A، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة تيترابينازين، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Sedation: Zanaflex may interfere with everyday activities; sedative effects of Zanaflex, alcohol, and other central nervous system (CNS) depressants are additive ( 5.3 , 7.4 ) (نشرة تيزانيدين، التحذيرات والاحتياطات)

Although behaviors such as “sleep-driving” may occur with temazepam capsules alone at therapeutic doses, the use of alcohol and other CNS depressants with temazepam capsules appear to increase the risk of such behaviors, as does the use of temazepam capsules at doses exceeding the maximum recommended dose. (نشرة تيمازيبام، التحذيرات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (نشرة ثيوثيكسين، التحذيرات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

25% increase Diazepam Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors. (نشرة ثيوفيلين، التداخلات الدوائية)

Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with valproic acid oral solution (7.2) (نشرة حمض الفالبرويك، التداخلات الدوائية)

Risk increases when used with other central nervous system (CNS) depressants. (نشرة داريدوريكسانت، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (نشرة دروبيريدول، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (نشرة درونابينول، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (نشرة ديازيبام، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other Drugs that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide,… (نشرة ديسموبريسين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Dosage adjustment of amitriptyline/nortriptyline, propofol, warfarin, and zidovudine may be necessary if used concomitantly with Depakote ER ( 7.2 ) (نشرة ديفالبروكس (فالبروات)، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. (نشرة ديكسميديتوميدين، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة ديوتيترابينازين، التحذيرات والاحتياطات)

The use of alcohol and other CNS depressants may increase the risk of such behaviors. (نشرة راميلتيون، التحذيرات والاحتياطات)

Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ASPRUZYO Sprinkle. (نشرة رانولازين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) ( See CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION . ) Serotonergic Drugs ( See CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION . ) (نشرة نورتريبتيلين، التداخلات الدوائية)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (نشرة ريفابنتين، التداخلات الدوائية)

…Selective 5-HT 3 Receptor Antagonists Ondansetron Decrease exposure Statins Metabolized by CYP3A4 Simvastatin Decrease exposure Thiazolidinediones Rosiglitazone Decrease AUC by 66% Tricyclic Antidepressants Nortriptyline A tuberculosis treatment regimen including rifampin (600 mg/day), isoniazid (300 mg/day), pyrazinamide (500 mg 3× per day), and pyridoxine (25… (نشرة ريفامبيسين، التداخلات الدوائية)

Monoamine Oxidase Inhibitors (MAOIs) ( See CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION . ) Serotonergic Drugs ( See CONTRAINDICATIONS , WARNINGS , and DOSAGE AND ADMINISTRATION . ) (نشرة نورتريبتيلين، التداخلات الدوائية)

Caution should be used when ZONISADE is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, carbonic anhydrase inhibitors and drugs with anticholinergic activity. (نشرة زونيساميد، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (نشرة سكسينيل كولين، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

The efficacy of tricyclic antidepressants can decrease when coadministered with sulfamethoxazole and trimethoprim. (نشرة سلفاميثوكسازول وتريميثوبريم، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (نشرة سوغاماديكس، التحذيرات والاحتياطات)

Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression. (نشرة سوفوريكسانت، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (نشرة سيفوفلوران، التحذيرات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressant. (نشرة نورتريبتيلين، التداخلات الدوائية)

Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology ( 12.3 )] . (نشرة سيناكالسيت، التداخلات الدوائية)

Concomitant use with other CNS depressants or alcohol may have additive effects. (نشرة سينوبامات، التحذيرات والاحتياطات)

When the decision is made to co-prescribe NEURONTIN with another CNS depressant, particularly an opioid, or to prescribe NEURONTIN to patients with underlying respiratory impairment, monitor patients for symptoms of respiratory depression and sedation, and consider initiating NEURONTIN at a low dose. (نشرة غابابنتين، التحذيرات والاحتياطات)

Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (نشرة غيفيتينيب، التداخلات الدوائية)

Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (نشرة فازوبريسين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (نشرة فالبينازين، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (نشرة فلوفينازين، التحذيرات)

Amitriptyline, nortriptyline Fluconazole increases the effect of amitriptyline and nortriptyline. (نشرة فلوكونازول، التداخلات الدوائية)

Exacerbated by other CNS depressants, and in settings where flibanserin concentrations are increased. (نشرة فليبانسيرين، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Eszopiclone (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased which may Increase the Sedative Effect of Eszopiclone Dose reduction of eszopiclone is recommended. (نشرة فوريكونازول، التداخلات الدوائية)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (نشرة فوسفومايسين، التداخلات الدوائية)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (نشرة فوسفينيتوين، التداخلات الدوائية)

…prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (نشرة فوسكارنت، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Acute cardiac arrest may be possible during treatment with tricyclic antidepressants; therefore, Anticholium should only be considered as an antidote for this indication while the patient has continuous ECG monitoring. (نشرة فيزوستيغمين، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

…Ethosuximide, felbamate, oxcarbazepine, methsuximide, topiramate Azoles Fluconazole, ketoconazole, itraconazole, miconazole, voriconazole Antineoplastic agents Capecitabine, fluorouracil Antidepressants Fluoxetine, fluvoxamine, sertraline Gastric acid reducing agents H 2 antagonists (cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine,… (نشرة فينيتوين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (نشرة كاربيدوبا، التحذيرات)

• Tricyclic antidepressants: risk of hypertension and dyskinesia reported during concomitant use with carbidopa/levodopa ( 7.4 ) (نشرة كاربيدوبا وليفودوبا وإنتاكابون، التداخلات الدوائية)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use VRAYLAR with caution in patient who may experience these conditions. (نشرة كاريبرازين، التحذيرات والاحتياطات)

• Additive sedative effects when used with other CNS depressants including alcohol (5.1) (نشرة كاريزوبرودول، التحذيرات والاحتياطات)

Other CNS depressants, including alcohol, could potentiate the somnolence and sedation effect of EPIDIOLEX. (نشرة كانابيديول (بوصفة طبية)، التحذيرات والاحتياطات)

Risk may be increased with concomitant use of other CNS depressants ( 5.4 , 5.5 ) (نشرة كلوبازام، التحذيرات والاحتياطات)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (نشرة كلورازيبات، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (نشرة كلورديازيبوكسيد، التحذيرات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.) The concomitant use of alcohol or other central nervous system depressants may have an additive effect. (نشرة كلورزوكسازون، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (نشرة كلوروبروكايين، الاحتياطات)

They should also be warned about the concomitant use of alcohol or other CNS-depressant drugs during Klonopin therapy (see PRECAUTIONS: Drug Interactions and PRECAUTIONS: Information for Patients ). (نشرة كلونازيبام، التحذيرات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Sympathomimetics, postganglionic blocking agents, and tricyclic antidepressants: Concomitant administration may increase the risk of cardiovascular adverse reactions. (نشرة كوكايين، التداخلات الدوائية)

• Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, or constipation (5.20) (نشرة كويتيابين، التحذيرات والاحتياطات)

Activation of Mania/Hypomania Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. (نشرة لوراسيدون، التحذيرات والاحتياطات)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (نشرة لوفيكسيدين، التحذيرات والاحتياطات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (نشرة لوكسابين، التحذيرات)

Monitor all antidepressant-treated patients, especially during the initial few months of anti-depressant drug therapy, and at times of dosage changes. (نشرة لوماتيبيرون، التحذيرات والاحتياطات)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (نشرة ليدوكايين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليفوثيروكسين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Risk increases with dose and use with other central nervous system (CNS) depressants. (نشرة ليمبوريكسانت، التحذيرات والاحتياطات)

Antidepressant Therapy Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and liothyronine sodium may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. (نشرة ليوثيرونين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (نشرة موكسيفلوكساسين، التحذيرات والاحتياطات)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (نشرة ميبروبامات، التحذيرات)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (نشرة ميبيفاكايين، التحذيرات)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (نشرة ميتيروسين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1) ]. (نشرة ميثوكاربامول، التحذيرات والاحتياطات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (نشرة ميفلوكين، التداخلات الدوائية)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (نشرة نالوكسون، التحذيرات والاحتياطات)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (نشرة نيوستيغمين، التحذيرات والاحتياطات)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (نشرة هالوبيريدول، التحذيرات)

Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (نشرة نورتريبتيلين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (نشرة إيبويتين ألفا، التحذيرات والاحتياطات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Appropriate care is advised when prescribing ERZOFRI to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (نشرة باليبيريدون، التحذيرات والاحتياطات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (نشرة نورتريبتيلين، التحذيرات)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Pamelor, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (نشرة تولكابون، الاحتياطات)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (نشرة تياغابين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (نشرة تيربينافين، التداخلات الدوائية)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (نشرة دوكسابرام، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (نشرة دونيبيزيل، التداخلات الدوائية)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Pamelor, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Pamelor, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (نشرة سيفيميلين، التداخلات الدوائية)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (نشرة غالانتامين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (نشرة لوفاستاتين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (نشرة نورتريبتيلين، التداخلات الدوائية)

NAMZARIC may interfere with anticholinergic medications. (نشرة ميمانتين ودونيبيزيل، التداخلات الدوائية)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

The antihypertensive action of guanethidine and similar agents may be blocked. (نشرة نورتريبتيلين، التحذيرات)

No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa and dopa-decarboxylase inhibitor. (نشرة إنتاكابون، الاحتياطات)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (نشرة روبينيرول، التداخلات الدوائية)

Sedatives/Hypnotics: midazolam (oral) triazolam ↑ midazolam (oral) ↑ triazolam Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA 7.4 Drugs without Clinically Significant Interactions with SUNLENCA Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with:… (نشرة ليناكابافير، التداخلات الدوائية)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (نشرة مونتيلوكاست، التداخلات الدوائية)